



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL820014677US
Express Mail Label Number

October 18, 2001
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#13

IN RE APPLICATION OF

Art Unit: 1643

DIGAN ET AL.

Examiner: Ewoldt, G.

APPLICATION NO: 09/480,236

FILED: JANUARY 10, 2000

FOR: ANTI-CD3 IMMUNOTOXINS AND THERAPEUTIC USES
THEREFOR

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
OCT 22 2001
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).


It is noted that EP 669,316 is in French; however, it includes a set of claims in English. As stated in the previously submitted IDS, EP 669,316 is a substantial equivalent of US Patent 5,637,613.

Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$180.00 for payment of the fee required by 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge the above-mentioned \$180.00 fee and any additional fees which may be required to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6765


Thomas R. Savitsky
Attorney for Applicants
Reg. No. 31,661

Date: October 18, 2001

Encls.: additional copy of this paper
PTO 1449 form